Rockefeller-Born, IPO-Validated Biodefense & Drug Discovery Biotechnology
With failure rates approaching 98% across the pharmaceutical industry, the drug discovery process is in dire need of improvement at every stage. AI-driven discovery remains constrained by the same flawed datasets.
DRUG DISCOVERY | TECHBIO
Invented in a Nobel Prize-winning laboratory at The Rockefeller University, our TRL9 biotechnology fixes the fundamental starting point: the Cell itself. We engineer human-relevant disease models that generate reliable data for drug discovery, techbio, and AI. Scale up of the FDA-validated discovery capability allows creation of a drug discovery funnel across clinical indications.
Fully resourced, the technology can be used to defeat new warfare neurotoxins adversaries may generate using AI. Tens of thousands of cell lines for all biological targets in the CNS may be created to identify toxin bioactivity and match it with FDA drugs for repurposing as immediately available countermeasures. Robotics and AI are available. Cells provide the missing link.
.png){kind=logo}